Apellis, CHMP
Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy,
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...
Apellis has said it will seek a re-examination of the CHMP’s opinion, noting that there were “multiple dissenting voices” by members of the panel. It also said that specialists at an ad hoc ...
The firm's stance comes ahead of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) expected final opinion on the approval of Apellis's drug pegcetacoplan ...
1 Day APLS -8.10% DJIA -0.14% S&P 500 -0.24% Health Care/Life Sciences 0.99% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apellis said it was expecting the CHMP’s decision after the panel indicated it was minded to reject the application in December and added that it would seek “immediate re-examination” of the ...
Mizuho has reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ: NASDAQ:APLS) with a steady price target of $42.00. The firm's stance comes ahead of the European Medicines Agency's (EMA) ...
WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback